Colorectal cancer and therapy response: a focus on the main mechanisms involved
Frontiers in Oncology · 19.07.2023 · 13
DOI: 10.3389/fonc.2023.1208140 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 19.07.2023. Verfasst von Sara Tirendi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Medicine, University of Genoa, Genoa, Italy. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 146 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
The latest GLOBOCAN 2021 reports that colorectal cancer (CRC) is the second leading cause of cancer-related death worldwide. Most CRC cases are sporadic and associated with several risk factors, including lifestyle habits, gut dysbiosis, chronic inflammation, and oxidative stress.
Aim
To summarize the biology of CRC and discuss current therapeutic interventions designed to counteract CRC development and to overcome chemoresistance.
Methods
Literature searches were conducted using PubMed and focusing the attention on the keywords such as “Current treatment of CRC” or “chemoresistance and CRC” or “oxidative stress and CRC” or “novel drug delivery approaches in cancer” or “immunotherapy in CRC” or “gut microbiota in CRC” or “systematic review and meta-analysis of randomized controlled trials” or “CSCs and CRC”. The citations included in the search ranged from September 1988 to December 2022. An additional search was carried out using the clinical trial database.
Results
Rounds of adjuvant therapies, including radiotherapy, chemotherapy, and immunotherapy are commonly planned to reduce cancer recurrence after surgery (stage II and stage III CRC patients) and to improve overall survival (stage IV). 5-fluorouracil-based chemotherapy in combination with other cytotoxic drugs, is the mainstay to treat CRC. However, the onset of the inherent or acquired resistance and the presence of chemoresistant cancer stem cells drastically reduce the efficacy. On the other hand, the genetic-molecular heterogeneity of CRC often precludes also the efficacy of new therapeutic approaches such as immunotherapies. Therefore, the CRC complexity made of natural or acquired multidrug resistance has made it necessary the search for new druggable targets and new delivery systems.
Conclusion
Further knowledge of the underlying CRC mechanisms and a comprehensive overview of current therapeutic opportunities can provide the basis for identifying pharmacological and biological barriers that render therapies ineffective and for identifying new potential biomarkers and therapeutic targets for advanced and aggressive CRC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Experimental Medicine, University of Genoa, Genoa, Italy.
- Inter-University Center for the Promotion of the 3Rs Principles in Teaching & Research (Centro 3R), Genoa, Italy.
Zitieren
APA
Tirendi, S., Marengo, B., Domenicotti, C., Bassi, A. M., Almonti, V., & Vernazza, S. (2023). Colorectal cancer and therapy response: a focus on the main mechanisms involved. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1208140
Vancouver
Tirendi S, Marengo B, Domenicotti C, Bassi AM, Almonti V, Vernazza S. Colorectal cancer and therapy response: a focus on the main mechanisms involved. Frontiers in Oncology. 2023;13. doi:10.3389/fonc.2023.1208140
BibTeX
@article{Tirendi2023,
author = {Tirendi, Sara and Marengo, Barbara and Domenicotti, Cinzia and Bassi, Anna M and Almonti, Vanessa and Vernazza, Stefania},
title = {Colorectal cancer and therapy response: a focus on the main mechanisms involved},
journal = {Frontiers in Oncology},
year = {2023},
volume = {13},
doi = {10.3389/fonc.2023.1208140}
}
EUVIMED